1 January 2023 in Immunologiya
Оценка эффективности различных адъювантов при получении мышиных моноклональных антител к рецептор-связывающему домену S-белка SARS-CоV-2
1 December 2024 in Molecular Genetics, Microbiology and Virology
Brucellosis is a zoonotic disease caused by Brucella. In the Russian Federation, a live vaccine based on the attenuated strain B. abortus 19BA is used to p
30 August 2026 in Journal of microbiology, epidemiology and immunobiology
ЛСЛутчева Ирина Сергеевна
ФВФирстова Виктория Валерьевна
Фирстова Виктория Валерьевна
+16
Introducion. Ricin is a glycoprotein phytotoxin that is characterised by high toxicity and relatively simple extraction methods. Monoclonal antibodies (mAbs) against ricin represent a key component in the development of immunodiagnostic test systems and preparations for the specific prevention and treatment of toxin poisoning. The aim of the present study was to obtain and characterise mouse monoclonal antibodies specific to the ricin B subunit. Materials and methods. Monoclonal antibodies were produced using a hybridoma technology, with the recombinant ricin B subunit (RTB) having been used as the antigen for immunising BALB/c mice. Hybridisation was performed by electrofusion, using the Sp2/0-Ag14 myeloma cell line as the partner cells. The stable hybridoma production was then carried out in vivo in mice. The specificity of the obtained mAbs was then assessed by Western blotting against RTB and native ricin. The parameters of the affinity interaction between the obtained antibodies and RTB were determined by surface plasmon resonance. The selection of the optimal antibodies pair for RTB detection was determined using a sandwich-format enzyme-linked immunosorbent assay (ELISA). In order to assess the neutralising activity of the antibodies against ricin, in vitro tests were carried out using the Vero В cell line, and in vivo tests were conducted using a mouse model. Results. Consequently, 13 mAbs specific to RTB and ricin were obtained and characterised. Following a thorough evaluation of the strength of affinity interaction and the selection of optimal antibody combinations for RTB detection, it was determined that four mAbs (RTB-F1-2, RTB-F1-16, RTB-F2-10 and RTB-F5-1) were identified as promising candidates for the purpose of developing diagnostic test systems. mAbs RTB-F1-15, RTB-F1-16, RTB-F2-10 and RTB-F5-1 demonstrated significant neutralising activity in in vitro tests against ricin at a dose of 8 × IC50. Intravenous administration of the mAbs RTB-F2-10 ensured 100% survival of mice following intraperitoneal ricin intoxication at a dose of 3 × LD50. Conclusion. The feasibility of utilising high-affinity mAbs (RTB-F1-2, RTB-F1-16, RTB-F2-10 and RTB-F5-1) for the design of diagnostic test systems has been demonstrated through experimental means. The data obtained on the neutralising properties of the mAb RTB-F2-10 in in vitro and in vivo tests allows it to be considered as a basis for the development of a therapeutic agent using chimerisation and humanisation strategies.
1 January 2026 in Immunologiya
1 October 2024 in Problems of Particularly Dangerous Infections
The aim of the work was to evaluate the ability of monoclonal antibodies to inhibit the interaction of the receptor binding domain (RBD) in S protein of SARS-CoV-2 virus variants, Wuhan-Hu-1 and BQ 1.1, with the angiotensin-converting receptor 2 (ACE2). Materials and methods. In this study, recombinant RBDs of Wuhan-Hu-1 and BQ 1.1 variants were used as antigens. For mouse monoclonal antibody (mMCA) production, hybridomas were cultured in vivo in BALB/c mice. mMCAs were isolated from ascitic fluid by ammonium sulfate treatment followed by purification through column affinity chromatography with Protein G Sepharose sorbent. The specific activity of mMCAs was assessed by immunoblot with recombinant RBD of Wuhan-Hu-1 variant. To identify the most promising mMCA, the neutralizing activity of mMCA was evaluated by enzyme-linked immunosorbent assay (ELISA) via immobilizing RBD on the surface of a microplate and using ACE2 in the form of horseradish peroxidase conjugate. Recombinant antigens were produced in ExpiCHO-S cell line (Gibco, USA). Results and discussion. Three mMCAs have been described as a result of the study: 5C3, 3F11, 1E6. All antibodies belong to immunoglobulins of subclass G and specifically interact with the RBD in S protein of SARS-CoV-2 virus. The most effective inhibition of the interaction between ACE2 and the RBD of BQ 1.1 strain was observed for murine MCA 3F11 (65 %), while the interaction with the RBD of Wuhan-Hu-1 strain was inhibited by mMCA 5C3 (91 %). The identified characteristics allow for considering the antibodies as potential candidates for the development of antibody-based therapeutics, thus expanding the possibilities of therapy for SARS-CoV-2 virus infection.
22 April 2024 in Molecular Genetics Microbiology and Virology (Russian version)
Brucellosis is a zoonotic disease caused by Brucella. In the Russian Federation, a live vaccine based on the attenuated strain B. abortus 19BA is used to prevent brucellosis in humans. However, pronounced reactogenicity and the likelihood of developing an infectious process after immunization make the creation of a safe subunit vaccine an urgent task. For this purpose, we created 47 recombinant brucellosis proteins and assessed their vaccine potential on a mouse cell culture. The aim of the study was to evaluate the immunogenic properties of recombinant Brucella proteins on cell culture and serum of BALB/c mice immunized with a Brucella vaccine strain. Materials and methods. Using reverse vaccinology methods, candidate brucellosis proteins were identified, a technology for their production and purification was developed. 47 single and fused recombinant proteins were obtained in the E. coli system of optimal concentration and purity for their further use in immune assays. To assess the immunogenicity of recombinant proteins, BALB/c mice were immunized with the B. abortus 19BA vaccine strain, and on the 30th day of infection, the blood serum and spleens of the animals were collected. The proteins were used as specific inducers for stimulating lymphocytes in in vitro experiments and antigens for determining serum antibody titers in immune and intact mice. The levels of IFN-γ and IL-4 cytokines in lymphocyte cell supernatants, as well as serum specific antibody titers, were analyzed by enzyme immunoassay. Results. The ability of 47 recombinant brucellosis proteins to induce the formation of humoral and cellular immune responses was assessed. As a result, 41 proteins activating the synthesis of IFN-γ and 8 proteins to which IgG antibodies are formed were identified. Conclusion. Brucellosis proteins capable of inducing a pronounced immune response in immunocompetent cells have been obtained and identified. These proteins can be considered as possible candidates for inclusion in vector, DNA and subunit vaccines against brucellosis in humans.